ReviewTherapeutic advances in musculoskeletal disease2020
Atypical femur fractures: current understanding and approach to management.
Review in Therapeutic advances in musculoskeletal disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- Plant-based macronutrients and micronutrients in combating osteoporosis: research insights and molecular pathways.RSC advances · 2026Review
- Risk factors for atypical femur fractures with and without bisphosphonate treatment: a national nested case-control study.JBMR plus · 2026Article
- Immune Checkpoint Inhibitors and Bone Health: Mechanisms, Clinical Implications, and Emerging Perspectives on Bone Fragility.Current osteoporosis reports · 2026Review
- Atypical femoral fracture: The periprosthetic variant about two cases without bisphosphonate use.SICOT-J · 2026Article
- Review
- Pathophysiology of Femoral Fractures in Hypophosphatasia.Current osteoporosis reports · 2025Review
- Bisphosphonate beak without the bisphosphonate: atypical femoral fracture with denosumab.BMJ case reports · 2025Article
- Atypical Femur Fracture in a Teenager on Chronic Imatinib Therapy.Case reports in oncological medicine · 2025Article
- Atypical femoral fracture in a patient with nutritional osteomalacia: a case report and literature review.Journal of surgical case reports · 2025Article
- Using DEXA to diagnose impending atypical femoral fracture in an asymptomatic patient on long term bisphosphonates: A case report of a missed opportunity for fracture prevention.Clinical case reports · 2024Article
- Comparison of bone turnover suppression in atypical femoral fractures and osteoporotic hip fractures.Scientific reports · 2024Article
- Prevalence and risk factors for atypical femoral fracture among Lebanese patients with hip and shaft fractures.JBMR plus · 2024Article
- Atypical femur fracture in a male without history of bisphosphonate use: a case report.Journal of medical case reports · 2024Article
- Review
- A summary of the Malaysian Clinical Practice Guidelines on the management of postmenopausal osteoporosis, 2022.Osteoporosis and sarcopenia · 2023Review
- Atypical Femoral Fracture in Hypophosphatasia: A Systematic Review.International journal of endocrinology · 2023Article
- Review on the protective activity of osthole against the pathogenesis of osteoporosis.Frontiers in pharmacology · 2023Review
- Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient With Hypophosphatasia.Journal of the Endocrine Society · 2022Article
- COVID-19 lockdown negatively impacted on adherence to denosumab therapy: incidence of non-traumatic fractures and role of telemedicine.Journal of endocrinological investigation · 2022Article
- Therapy-induced bone changes in oncology imaging withAnnals of nuclear medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis and resulting osteoporotic fractures are responsible for significant morbidity, excess mortality, and health care costs in the developed world. Medical therapy for osteoporosis has been shown in multiple randomized controlled trials to reduce the risk of vertebral and non-vertebral fractures and hip fractures, and in some studies bisphosphonate medications have been associated with improved survival. Although the overall benefit to risk ratio of osteoporosis medications remains favorable, there have been concerns raised about the long-term safety of these treatments. Atypical femur fracture, which is a rare type of fracture that has been associated with the long-term use of potent antiresorptive bone medications, is a potentially devastating consequence of osteoporosis treatment. This paper reviews our current understanding of atypical femur fractures, their relationship to antiresorptive osteoporosis medications, and proposed strategies for management, in order to inform clinical decision making about the optimal use and duration of medical therapy for the treatment of patients with osteoporosis or at high risk for osteoporotic fractures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.